Literature DB >> 17223424

Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy.

Angelo Auricchio1, Marco Metra, Maurizio Gasparini, Barbara Lamp, Catherine Klersy, Antonio Curnis, Cecilia Fantoni, Edoardo Gronda, Juergen Vogt.   

Abstract

This multicenter longitudinal observational trial was designed to analyze the long-term outcome of patients with heart failure (HF) treated with cardiac resynchronization therapy (CRT) alone or with implantable cardioverter-defibrillator (ICD) backup in a daily practice scenario. It is unknown whether the magnitude of survival benefits conferred by CRT in a daily practice scenario is comparable to what has been observed in randomized controlled trials and whether this benefit is sustained over the long term. The outcome of 1,303 consecutive patients with ischemic or nonischemic cardiomyopathy on optimal pharmacologic therapy treated from August 1, 1995 to August 1, 2004 at 4 European centers with CRT alone (44%) or with ICD backup for symptomatic HF and prolonged QRS duration was assessed. Cumulative event-free survival was evaluated for a combined end point, defined as death from any cause, urgent transplantation, or implantation of a left ventricular assist device. The cumulative incidence of competing events, HF, sudden cardiac death, and noncardiac death, was also assessed. Event-free survival was similar across the different centers. At 1 and 5 years, cumulative event-free survivals were 92% (95% confidence interval [CI] 91 to 94) and 56% (95% CI 48 to 64), respectively. The cumulative incidence of HF deaths was 25.1% (95% CI 19 to 31.7), whereas that of sudden death was 9.5% (95% CI 5.1 to 15.7). Using multivariate analysis, CRT with an ICD backup was associated with a nonsignificant decrease in mortality by 20% (hazard ratio 0.83, 95% CI 0.58 to 1.17, p = 0.284), with a highly significant protective effect against sudden cardiac death (hazard ratio 0.04, 95% CI 0.04 to 0.28, p <0.002). In conclusion, patients with advanced HF and a wide QRS complex routinely treated with CRT have a favorable long-term outcome that was reproducible at different centers. The leading cause of death in these patients remained HF, and this mode of death was competing with other causes in determining outcome. Total mortality was 20% lower with ICD backup (95% CI 42% lower to 17% higher) due to a protective effect against sudden cardiac death.

Entities:  

Mesh:

Year:  2006        PMID: 17223424     DOI: 10.1016/j.amjcard.2006.07.087

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

Review 1.  European cardiac resynchronization therapy survey: rationale and design.

Authors: 
Journal:  Eur J Heart Fail       Date:  2009-03       Impact factor: 15.534

Review 2.  Clinical, laboratory, and pacing predictors of CRT response.

Authors:  Jagdesh Kandala; Robert K Altman; Mi Young Park; Jagmeet P Singh
Journal:  J Cardiovasc Transl Res       Date:  2012-02-24       Impact factor: 4.132

Review 3.  Enhancing Cardiac Resynchronization Therapy for Patients with Atrial Fibrillation: The Role of AV Node Ablation.

Authors:  Jeff M Berry; Jose AJoglar
Journal:  J Atr Fibrillation       Date:  2012-04-14

Review 4.  The determinants of clinical outcome and clinical response to CRT are not the same.

Authors:  John G F Cleland; Stefano Ghio
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

5.  Meta-analysis of rate ratios with differential follow-up by treatment arm: inferring comparative effectiveness of medical devices.

Authors:  Lauren M Kunz; Sharon-Lise T Normand; Art Sedrakyan
Journal:  Stat Med       Date:  2015-05-24       Impact factor: 2.373

Review 6.  Cardiac Resynchronization in Patients with Atrial Fibrillation.

Authors:  S Serge Barold; Bengt Herweg
Journal:  J Atr Fibrillation       Date:  2015-12-31

7.  Efficacy of implantable cardioconverter defibrillator or cardiac resynchronization therapy compared with combined therapy in survival of patients with heart failure: a meta-analysis.

Authors:  Jin-Long Deng; Yin-Xiong Wu; Jie Liu
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

8.  EAARN score, a predictive score for mortality in patients receiving cardiac resynchronization therapy based on pre-implantation risk factors.

Authors:  Malek Khatib; José M Tolosana; Emilce Trucco; Roger Borràs; Angeles Castel; Antonio Berruezo; Adelina Doltra; Marta Sitges; Elena Arbelo; Maria Matas; Josep Brugada; Lluís Mont
Journal:  Eur J Heart Fail       Date:  2014-05-23       Impact factor: 15.534

Review 9.  Cardiac resynchronization therapy in heart failure patients with atrial fibrillation.

Authors:  Maurizio Gasparini; François Regoli; Paola Galimberti; Carlo Ceriotti; Alessio Cappelleri
Journal:  Europace       Date:  2009-11       Impact factor: 5.214

10.  Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation.

Authors:  Maurizio Gasparini; Angelo Auricchio; Marco Metra; François Regoli; Cecilia Fantoni; Barbara Lamp; Antonio Curnis; Juergen Vogt; Catherine Klersy
Journal:  Eur Heart J       Date:  2008-04-04       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.